Bitcoin sets a new all-time high above $6,000 >>> READ MORE

22 New Stocks to Watch – Mobileye, Synchrony Financial & More

This could be the biggest week for IPOs in 2014


Last week saw 10 IPOs hit the market with mixed results. While a handful did extremely well — such as El Pollo Loco (LOCO), which had a boffo first day — the overall performance was far from robust. In fact, seven companies had to price their IPOs below their proposed ranges.

But Wall Street isn’t slowing down — in fact, it’s adding more juice to the IPO machine. This week, we’ll see 22 new stocks hitting the market (including holdovers Atara Biotherapeutics, Mapi-Pharma and Spark Energy, which we talked about here).

Yet it seems like a good bet that the erosion will continue since plenty of the offerings are from small, experimental biotechs – which investors seem to be getting tired of.

So let’s take a deeper look at all of the upcoming IPOs:

New Stocks to Watch: Auris Medical (EARS)

Expected Offering Date: Friday

Auris Medical is a clinical-stage biotech operator that is targeting inner ear disorders. The lead candidate, AM-101, is currently in Phase 3 trials and is designed to treat inner ear tinnitus (ringing in the ears). Then there is AM-111, which is targeted at inner ear hearing loss, and Phase 3 clinical trials will begin for AM-111 in the fourth quarter of this year.

Both drugs involve injections under local anesthesia; the procedure is short and has a long history of use.

Auris plans to issue 6.9 million shares on the Nasdaq under the ticker “EARS” at a range of $10 to $12. Lead underwriters include Jefferies and Leerink Partners.

New Stocks to Watch: Avalanche Biotechnologies (AAVL)

Expected Offering Date: Thursday

Avalanche Biotechnologies is a biotech company that targets gene therapies for patients with sight-threatening ophthalmic diseases.

AAVL thinks its platform, which is called the Ocular BioFactory, will lead to a strong pipeline of new product candidates, each of

For each, there is a one-time administration to the eye.

The lead candidate is AVA-101, which is for wet age-related macular degeneration (AMD) and is in Phase 1 clinical trials. The global market is about $6 billion.

Avalanche expects to offer 5.4 million shares on the Nasdaq under the ticker “AAVL” at a range of $13 to $15. Lead underwriters include Jefferies, Cowen & Company and Piper Jaffray (PJC).

New Stocks to Watch: Bio Blast Pharma (ORPN)

Expected Offering Date: Friday

Bio Blast Pharma is a biotech company that is focused on treatments for rare and ultra-rare genetic diseases. Since 2012, Bio Blast has developed and in-licensed potential treatments for six diseases that are in either Phase 2 or Phase 3 trials. The drugs help with such disorders like oculopharyngeal muscular dystrophy, Machado Joseph disease, Kennedy’s disease, Friedrich’s ataxia and ornithine transcarbamylase deficiency.

Bio Blast Pharma plans to sell 3.3 million shares on the Nasdaq under the ticker “ORPN” at a range of $11 to $13. Lead underwriters include Oppenheimer and Roth Capital.

New Stocks to Watch: Catalent (CTLT)

Expected Offering Date: Friday

Catalent develops advanced delivery technologies for drugs, biologics and consumer health offerings. Some of the products include softgel capsules, Zydis oral dissolving tablets and blow-fill-seal unit dose liquids.

Last year, the company revenues were $1.8 billion and adjusted EBITDA came to $413 million. Some of the customers include biggies like Pfizer (PFE), Johnson & Johnson (JNJ) and Merck (MRK).

Catalent plans to issue 42.5 million shares on the New York Stock Exchange under the ticker “CTLT” at a range of $19 to $22. The lead underwriters include Morgan Stanley (MS), JPMorgan (JPM), BofA Merrill Lynch (BAC) and Goldman Sachs (GS).

New Stocks to Watch: FCB Financial Holdings (FCB)

Expected Offering Date: Friday

FCB Financial Holdings is a Florida-based bank that operates 54 branches. Since 2009, the firm has raised about $740 million and has purchased eight failed banks.

As of now, the bank has $5.17 billion in assets. The company’s profits have also been rising nicely. In 2013, they were $17.1 million, up from a $4.8 million loss in the year before.

FCB plans to issue 8.7 million shares at a range of $24.00 to $27.00. The lead underwriters include Deutsche Bank (DB), JPMorgan, BofA Merrill Lynch and UBS Investment Bank (UBS).

New Stocks to Watch: HealthEquity (HQY)

Expected Offering Date: Thursday

HealthEquity operates a cloud platform that allows consumers to make healthcare decisions, including working with healthcare savings accounts, bill comparisons and wellness incentives. The system is integrated with 20 of the 50 largest health plans in the U.S. and more than 25,000 employer clients like eBay (EBAY) and Google (GOOG).

In fiscal 2014, HealthEquity’s revenues increased by 35% to $62 million and adjusted EBITDA rose from $10.5 million to $15.8 million. The platform has more than 1 million HAS accounts.

HealthEquity plans to sell 9.1 million shares on the Nasdaq under the ticker “HQY” at a range of $10 to $12. Lead underwriters include JPMorgan and Wells Fargo Securities (WFC).

Next Page

1 2 3 View All

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC